Clinical trial
Hu-Mik-beta1 to Treat T-Cell Large Granular Lymphocytic Leukemia
NCT00076180 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00076180 |
|---|---|
| Title | Hu-Mik-beta1 to Treat T-Cell Large Granular Lymphocytic Leukemia |
| Official title | Phase I Open-Label Single-Dose Study of Humanized Mik-Beta-1 Monoclonal Antibody Directed Toward the IL-2R/IL-15R-Beta Subunit (CD122) in T Cell Large Granular Lymphocytic Leukemia |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | T-Cell Large Granular Lymphocytic Leukemia, Leukemia, T-Cell Large Granular Lymphocytic |
| Intervention type | Biological |
| Interventions | Hu-MiK-Beta-1 |
| Enrollment | 9 |
| Start date | Mar 1, 2004 |
| Primary completion | Nov 12, 2010 |
| Completion | Jan 9, 2019 |
| First posted | Jan 15, 2004 |
| Last update posted | Jan 11, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: